In the bio-tech market, Haleon PLC has undertaken a series of strategies to strengthen its financial position, majorly through share buyback programs where over 1.3 million shares were cancelled. Regular alongside, several insiders have procured company shares boosting confidence in the stock. The company's earnings growth passed the stock scan which suggests a good re-entry point for investors. Simultaneously, Haleon PLC has had some hits such as a fall in shares after a cut to organic revenue guidance and a lowered stock price target by Berenberg due to slow growth. Partnering with the Indian Dental Association for an international symposium and teaming up with Brightseed are also substantial moves. Pfizer ended its stake in Haleon by selling final shares worth $3.2B. Haleon completed the acquisition of the remaining stake in its China JV. On the downside, North America's weak demand led to a cut in revenue growth forecast.
Haleon Stocks News Analytics from Thu, 27 Feb 2025 08:00:00 GMT to Sat, 30 Aug 2025 23:01:45 GMT - Rating 2 - Innovation -1 - Information 4 - Rumor 0
